1 completed, 1 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Attralus, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis AT-02, AT-02 (Placebo) - Amyloidosis; Systemic | Phase 1 | Unknown | Attralus, Inc. | 100 | 2022-09-01 | 2024-04-03 |
| A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis 124I-AT03 - Amyloidosis; Systemic | Phase 1 | Completed | Attralus, Inc. | 13 | 2021-11-30 | 2022-09-15 |
Immunoglobulin Light-chain Amyloidosis (2) · Amyloidosis, Hereditary, Transthyretin-Related (1)
United States (2) · Australia (1)
Gregory Bell, MD (1)